Fibrosis: Cross-Organ Biology and Endpoint Alignment (Lung, Liver, Kidney)
​
Fibrosis research is evolving beyond single-organ thinking. Cross-organ biology now shapes how preclinical data is interpreted across lung, liver, and kidney models.
Read the full article here to explore how integrated endpoints improve translational confidence in fibrosis studies. Learn more about multi-system study design approaches.
#Fibrosis #PreclinicalResearch #DrugDevelopment #TranslationalScience #InVivoStudies
Respiratory Disease Models: Choosing Functional Readouts for ARDS, COPD, and IPF
​
Respiratory disease research depends on more than selecting a disease model. It requires aligning biology, mechanism, and functional outcomes to improve translational relevance.
Learn how ARDS, COPD, and IPF models can be paired with meaningful readouts to strengthen preclinical decision-making. Read the full article here to explore study design strategies.
Explore how better model selection can improve respiratory research outcomes. Visit the article for more insights.
#RespiratoryResearch #PreclinicalModels #DrugDevelopment #TranslationalScience #ARDSCOPDIPF
In Vitro Proarrhythmic Liability: Integrated with In Vivo Telemetry for Predictive Cardiac Safety
​
Proarrhythmic risk assessment is moving beyond QT alone. Integrated in vitro and in vivo approaches now provide a more complete view of cardiac safety.
This article explores how ion channel profiling, telemetry, and hemodynamics work together to improve translational predictivity. Read the full article here to learn more about modern cardiac safety frameworks.
#CardiacSafety #PreclinicalResearch #Pharmacology #DrugDevelopment #SafetyPharmacology
Pulmonary Hypertension Model Selection: PAH and CTEPH Research
​
Pulmonary hypertension research requires more than selecting a commonly used model. Translational relevance depends on matching pathophysiology, hemodynamics, and remodeling endpoints to your therapy’s mechanism of action.
This article explores key considerations for PAH and CTEPH model selection in preclinical development. Read the full article here to learn how tailored model strategies can strengthen translational confidence.
#PulmonaryHypertension #PAH #CTEPH #PreclinicalResearch #DrugDevelopment
​
Metabolic dysfunction in heart failure extends far beyond impaired cardiac mechanics. Mitochondrial stress, inflammation, insulin resistance, and systemic metabolic disruption all shape disease progression and therapeutic response.
This article explores what preclinical models can realistically tell us about metabolic heart failure, where translational gaps remain, and how integrated study design improves research relevance. Read the full article here.
#HeartFailureResearch #MetabolicHeartFailure #PreclinicalResearch #CardiometabolicDisease #TranslationalScience
​
HFpEF and HFrEF require fundamentally different preclinical strategies. Model selection, induction methods, and endpoint design all influence translational confidence before clinical development begins.
Learn how translationally relevant heart failure models can improve preclinical decision-making and therapeutic evaluation. Read the full article here.
#HFpEF #HFrEF #PreclinicalResearch #CardiovascularResearch #DrugDevelopment
​
Understanding the difference between GLP and non-GLP studies is essential for building a strong preclinical strategy. Study design, QA oversight, and documentation standards can directly affect regulatory readiness and downstream development risk.
This article breaks down how GLP changes operational expectations in efficacy and safety studies, and why the distinction matters during IND-enabling development. Read the full article here
#GLP #PreclinicalResearch #DrugDevelopment #TranslationalResearch #Biotech
In Vivo Disease Model: Reduce Late-Stage Risk with the Right Translational Choice
​
Late-stage failures often begin with poor translational alignment in preclinical research. Choosing the right in vivo disease model can improve predictive value and strengthen development decisions earlier in the pipeline.
Learn how translational model selection helps reduce risk and support more clinically relevant outcomes. Read the full article here.
#PreclinicalResearch #DrugDevelopment #TranslationalScience #InVivoModels #Biotech